Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III – N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era

Ähnliche Einträge

• Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma
  von: Jianwei Liu, et al.
  Veröffentlicht: (2026)
• Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy
  von: Guo Lin, et al.
  Veröffentlicht: (2026)
• The Illusion of Residual Disease: An Unusual Pattern of Histologic Response to Neoadjuvant Immunotherapy in Resectable Stage III Melanoma
  von: Maria Kostaki, et al.
  Veröffentlicht: (2025)
• A Meta‐Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non‐Small Cell Lung Cancer
  von: Xinru Sun, et al.
  Veröffentlicht: (2024)
• Toll‐Like Receptors in the Immunotherapy Era: Dual‐Edged Swords of Tumor Immunity and Clinical Translation
  von: Nueraili Maihemuti, et al.
  Veröffentlicht: (2025)